STW204/Gotistobart

N/A

Report date: 2024/02/04 17:57:56

Base Information

Drug NameSTW204/Gotistobart
Drug Alias NameAI-061
ClassificationBiologics
Mechanisms of ActionProgrammed cell death protein 1 blockersCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsYes STW204Gotistobart
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncoc4 Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncoc4 Inc
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[18] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A